RS
JSPR icon

R Squared’s Jasper Therapeutics JSPR Stock Holding History

R Squared’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-720
Closed -$15.4K – 905
2024
Q4 		$15.4K Buy
+720
New +$15K 0.02% 1001

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

R Squared's JSPR Position: Q1 2025 in Review

R Squared sold out of Jasper Therapeutics (JSPR) in Q1 2025, closing a stake of 720 shares — an estimated $15.4K sold.

R Squared first reported a position in JSPR in Q4 2024 and held it in 1 quarter. The position peaked at $15.4K in Q4 2024. 68 funds tracked by Wall St. Rank hold JSPR as of Q1 2025.

  • R Squared reported no remaining Jasper Therapeutics position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 720 Jasper Therapeutics shares in Q1 2025, an estimated $15.4K.
  • R Squared first reported a position in Jasper Therapeutics in Q4 2024 and held it in 1 quarter.
  • R Squared's Jasper Therapeutics position peaked at $15.4K in Q4 2024.
  • 68 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.